AmbioPharm (688076)
AmbioPharm (688076)
Jiangsu · No. 28, Lianyungang Economic and Technological Development Zone Linpu Road, China
Overview
Sinopep-Allsino Biopharmaceutical is a global commercial API provider and full-service CDMO focused on end-to-end CMC development and commercial production of peptides, oligonucleotides and small molecule APIs. Serving global innovative pharmaceutical companies since 2009, it has passed four US FDA inspections and strictly follows FDA and ich guidelines. The peptide production capacity reaches 20–30 metric tons per year; a large-scale GMP oligonucleotide base has been built in Lianyungang, Jiangsu Province (annual output can reach thousands of kilograms, containing ASO, siRNA, GalNAc, AOC, liposomes and other conjugates). Services cover polypeptide/oligonucleotide CDMO, FTE, discovery services, generic APIs and preparations (oral solid preparations, lyophilized powder injections, etc.), providing process development, analytical method development and validation, stability research, and IND/NDA regulatory support to achieve a seamless connection from early development to commercial supply.
Peptides produced
Notes
AmbioPharm (688076) is located at No. 28, Lianyungang Economic and Technological Development Zone Linpu Road, China.
Main peptides produced: Cagrilintide, Tirzepatide, Retatrutide, Semaglutide, Liraglutide.
Website: https://www.sinopep.com